Jupiter Life Line Hospitals (JLHL) investor relations material

Executive summary

• Dombivli Hospital completed its first full quarter, contributing an EBITDA loss of ₹9.5 crore, with occupancy and patient footfall rising as expected.

• Established hospitals maintained healthy occupancy, providing operational and financial stability.

• Consolidated revenue from operations for Q1 FY27 was ₹4,109.83 million, up from ₹3,529.53 million in Q1 FY26.

• Net profit attributable to owners for Q1 FY27 was ₹374.86 million.

• The group completed the acquisition of Sulcus Private Limited to set up a pharmaceutical manufacturing facility, aiming to reduce costs and improve margins.

Financial highlights

• Total income for Q1 FY27 was ₹411 crore, with revenue from operations at ₹392.6 crore, up 16.2% year-over-year.

• EBITDA for Q1 FY27 was ₹79.3 crore, margin at 19.3%, down from 22.2% year-over-year due to ramp-up losses and higher marketing costs.

• PAT for Q1 FY27 was ₹37.5 crore, down 14.7% year-over-year; PAT margin at 9.1%.

• Basic and diluted EPS for Q1 FY27 was ₹5.72, compared to ₹6.69 in Q1 FY26.

• Depreciation and finance costs increased due to new bed additions and expansion-related debt.

Outlook and guidance

• Dombivli Hospital expected to reach EBITDA breakeven in 1.5 to 2 years; guidance unchanged despite strong initial ramp-up.

• Insurance empanelment at Dombivli is expected to boost patient inflows in coming quarters.

• Phased development continues with new specialties and consultant expansion to support steady ramp-up.

• Pune South, Mira Road, and BKC projects progressing as planned.

• The group is expanding into pharmaceutical manufacturing to support hospital operations and improve cost efficiency.